Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Novartis
Fuji
Farmers Insurance
Teva
QuintilesIMS
Deloitte
Medtronic
Express Scripts
Covington

Generated: October 20, 2017

DrugPatentWatch Database Preview

Rucaparib camsylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rucaparib camsylate and what is the scope of rucaparib camsylate patent protection?

Rucaparib camsylate
is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and twenty-six patent family members in fifty-two countries and twelve supplementary protection certificates in eleven countries.

One supplier is listed for this compound.

Summary for Generic Name: rucaparib camsylate

US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list15
Drug Prices:see low prices
DailyMed Link:rucaparib camsylate at DailyMed

Pharmacology for Ingredient: rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► SubscribeYY ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Clovis Oncology Inc
RUBRACA
rucaparib camsylate
TABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: rucaparib camsylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,169,235Phthalazinone derivatives► Subscribe
6,977,298 Tricyclic inhibitors of poly(ADP-ribose) polymerases► Subscribe
7,449,464Phthalazinone derivatives► Subscribe
7,429,578Tricyclic inhibitors of poly(ADP-ribose) polymerases► Subscribe
7,981,889Phthalazinone derivatives► Subscribe
8,912,187Phthalazinone derivatives► Subscribe
9,566,276Phthalazinone derivatives► Subscribe
7,662,818Phthalazinone derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: rucaparib camsylate

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005053662► Subscribe
Luxembourg92680► Subscribe
Cyprus1111597► Subscribe
China1856572► Subscribe
Russian Federation2570198► Subscribe
Serbia55487► Subscribe
Spain2364140► Subscribe
Brazil0008614► Subscribe
United Kingdom0603874► Subscribe
Denmark1684736► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RUCAPARIB CAMSYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/016Ireland► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
/2015Austria► SubscribePRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
500012Hungary► SubscribePRODUCT NAME: OLAPARIB
00726Netherlands► SubscribePRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
680Luxembourg► SubscribePRODUCT NAME: OLAPARIB AINSI QUE DES SELS ET DES SOLVATES DE CELUI-CI. FIRST REGISTRATION: 20141218
3 50005-2015Slovakia► SubscribePRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
2015016Lithuania► SubscribePRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
0150012 00136Estonia► SubscribePRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
90019-4Sweden► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
2015 00012Denmark► SubscribePRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
McKinsey
Fish and Richardson
UBS
Argus Health
Queensland Health
Dow
McKesson
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot